• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Passage Bio, Inc. - Common Stock (NQ:PASG)

12.87 -1.41 (-9.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Passage Bio, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
November 10, 2025
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
November 05, 2025
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference
October 14, 2025
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
August 28, 2025
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights
August 12, 2025
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Announces 1-for-20 Reverse Stock Split
July 10, 2025
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
June 23, 2025
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights
May 13, 2025
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
March 04, 2025
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Participate in Upcoming Investor Conferences
February 26, 2025
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
January 10, 2025
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
November 13, 2024
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
November 06, 2024
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
October 24, 2024
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
September 23, 2024
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)
September 16, 2024
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Welcomes Tom Kassberg to Board of Directors
September 10, 2024
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
August 30, 2024
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
August 08, 2024
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Participate in Upcoming Investor Conferences
August 06, 2024
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
August 01, 2024
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
July 16, 2024
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
May 14, 2024
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
April 22, 2024
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
March 04, 2024
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Participate in Upcoming Investor Conferences
February 27, 2024
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
December 20, 2023
From Passage Bio
Via GlobeNewswire
News headline image
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
November 17, 2023
From Passage Bio
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap